ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZAtm (vimseltinib), a kinase ...

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...

Atherosclerotic cardiovascular disease is a major health concern worldwide and requires effective preventive measures. Lp(a) (lipoprotein [a]) has recently garnered attention as an independent risk ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

A teenage girl presented to the hospital emergency department with a three-week history of intermittent frontal headache, which was worse in the morning and associated with nausea, vomiting, lethargy, ...

Why do cancer treatments stop working? In an interview with HT Lifestyle, Dr Anjali Kulkarni, Vice President - RWE Strategy and Analytics and Oncologist at 4baseCare, expalined, “Drug resistance ...

Inc. reported its Q1 FY2025 earnings, revealing a net loss per share of $0.06, which was better than the projected loss of $0.08. The company's revenue reached $3.2 million, surpassing the forecast of ...

Megakaryocytes form a three-dimensional (3D) cage composed of laminin and collagen IV connected to the basement membrane surrounding them. This microarchitecture stabilizes megakaryocytes within their ...

High-quality mechanistic and clinically relevant science to keep clinicians at the forefront of the latest advancements in the diagnosis and treatment of heart failure ...

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...